TerSera Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- TerSera Therapeutics's estimated annual revenue is currently $31M per year.
- TerSera Therapeutics's estimated revenue per employee is $201,000
Employee Data
- TerSera Therapeutics has 154 Employees.
- TerSera Therapeutics grew their employee count by 6% last year.
TerSera Therapeutics Competitors & Alternatives
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $69.5M | 346 | -3% | N/A | N/A |
#2 | $15.3M | 76 | -20% | $35M | N/A |
#3 | $4.2M | 21 | -5% | N/A | N/A |
#4 | $21.7M | 108 | -11% | N/A | N/A |
#5 | $12.7M | 63 | -10% | N/A | N/A |
#6 | $10.5M | 52 | -7% | N/A | N/A |
#7 | $14.3M | 71 | -4% | N/A | N/A |
#8 | $26.3M | 131 | -5% | N/A | N/A |
#9 | $200.6M | 998 | 0% | N/A | N/A |
#10 | $18.7M | 93 | N/A | N/A | N/A |
What Is TerSera Therapeutics?
TerSera Therapeutics acquires and develops specialty pharmaceutical products with a focus on select therapeutic areas. Our mission is to market products which truly make a difference for patients. Our focus is to bring intelligent solutions to prescribers and patients who need better solutions. We deliver a comprehensive set of programs that go beyond the therapy itself in order to provide improved outcomes for patients.
keywords:N/AN/A
Total Funding
154
Number of Employees
$31M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
TerSera Therapeutics News
Goserelin Market SWOT Analysis including key players AstraZeneca, TerSera Therapeutics, Luye Pharma A Comprehensive Study exploring ...
Meloxicam Drug Market Latest Trend with Top key players: Boehringer-Ingelheim, TerSera Therapeutics, Iroko Pharmaceuticals, Apotex, Yung ...
Plenty of Opportunities in Meloxicam Drug Market Studied in Detail along with Top Companies as Boehringer-Ingelheim, TerSera Therapeutics, ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $42.5M | 154 | -7% | N/A |
#2 | $47.5M | 170 | 0% | N/A |
#3 | $48.1M | 173 | 4% | N/A |
#4 | $42.6M | 176 | 27% | N/A |
#5 | N/A | 186 | 9% | N/A |